Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 7/20 | 0.33 |
| ▸ | IDH2 | P48735 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12886386 | 0.84 | — | — | |
| SCHEMBL15426694 | 0.84 | — | — | |
| SCHEMBL13431718 | 0.74 | ALDH1A1 (0.38) | EPHX2IDH1IDH2 | |
| SCHEMBL12819706 | 0.72 | EPHX2 (0.36) | EPHX2IDH1IDH2 | |
| Hydrochloric Acid SCHEMBL3235396 | 0.72 | ALDH1A1 (0.36) | EPHX2IDH1IDH2 | |
| SCHEMBL19687459 | 0.72 | EPHX2 (0.40) | EPHX2IDH1IDH2 | |
| SCHEMBL1717640 | 0.72 | EPHX2 (0.36) | EPHX2IDH1IDH2 | |
| SCHEMBL13178176 | 0.72 | EPHX2 (0.37) | EPHX2 | |
| SCHEMBL178464 | 0.72 | EPHX2 (0.40) | EPHX2IDH1IDH2 | |
| SCHEMBL27573855 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850277-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017162156-A1 | IRIDINESULFONAMIDE COMPOUND AND USE METHOD THEREOF | 正大天晴药业集团股份有限公司 | 2017-09-28 | — | — | WO | disclosed |
| US-20170057994-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-03-02 | — | — | US | disclosed |
| US-20170015703-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-01-19 | — | — | US | disclosed |
| US-9474779-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160130298-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-05-12 | — | — | US | disclosed |
| US-20150031627-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2015010297-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090318494-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| WO-2008015416-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-02-07 | — | — | WO | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | EPHX2 953/4885IDH1 3065/4885IDH2 3004/4885 |
| US-20150031627-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | EPHX2 1564/4885IDH1 1/4885IDH2 4/4885 |
| US-20170015703-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | EPHX2 1366/4885IDH1 1/4885IDH2 4/4885 |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | EPHX2 155/4885IDH1 2916/4885IDH2 2870/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | EPHX2 1135/4885IDH1 588/4885IDH2 497/4885 |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | PDE4B, PDE3B, PDE4A | EPHX2 186/4885IDH1 2578/4885IDH2 2049/4885 |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | EPHX2 1384/4885IDH1 1459/4885IDH2 1117/4885 |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | PDE4A, PDE4B, PDE3B | EPHX2 956/4885IDH1 2315/4885IDH2 1728/4885 |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | PDE5A, PDE3B, PDE4A | EPHX2 1107/4885IDH1 2358/4885IDH2 2289/4885 |
| US-20090318494-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | EPHX2 1164/4885IDH1 1667/4885IDH2 833/4885 |
| US-20160130298-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | EPHX2 1366/4885IDH1 1/4885IDH2 4/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | EPHX2 1686/4885IDH1 1/4885IDH2 4/4885 |
| US-20170057994-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | EPHX2 1564/4885IDH1 1/4885IDH2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.